We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SPEN:TASEShapir Engineering and Industry Ltd Analysis

Data as of 2026-05-22 - not real-time

ILA 4,123.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

SPEN is trading at 4,123 ILA, comfortably above the computed support of 3,963 and below the 52‑week high of 4,627. The 20‑day SMA (4,267) sits above the 50‑day SMA (3,950), confirming a short‑term bullish bias, while the 200‑day SMA (3,205) remains well below price, supporting a longer‑term uptrend. Momentum indicators are mixed: the RSI at 47 suggests neutral pressure, but the MACD histogram is negative (‑48) with the line below its signal, hinting at possible downside momentum. Volume has been stable, and the beta of roughly 0.09 indicates the stock moves less than the market. Overall, technicals point to a fragile bullish stance that could be tested if price approaches the 3,963 support.
Fundamentally, SPEN posted 23.6% revenue growth and a modest operating margin of 10%, yet its price‑to‑earnings ratio of 63.4 dwarfs the industry average of 29.7, and the discounted cash‑flow model values the company at only ~668 ILA, implying severe overvaluation. The balance sheet is heavily leveraged, with a debt‑to‑equity of 278 and total debt exceeding cash by roughly ten‑fold, while free cash flow is slightly negative, raising concerns about dividend sustainability despite a 0.59% yield and a 34% payout ratio. Volatility over the past 30 days stands at 28%, and the fear‑and‑greed index reads “Extreme Greed,” underscoring market euphoria. These fundamentals suggest that the upside potential is limited until valuation compresses or leverage improves.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near technical support
  • Bearish MACD histogram
  • Neutral RSI

Medium Term

1–3 years
Neutral
Model confidence: 4/10

Key Factors

  • Strong revenue growth
  • High debt-to-equity ratio
  • Valuation gap vs DCF

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Severe overvaluation relative to fundamentals
  • Unsustainable dividend given negative free cash flow
  • Elevated leverage limiting future earnings

Key Metrics & Analysis

Financial Health

Revenue Growth23.60%
Profit Margin3.87%
P/E Ratio63.4
ROE7.09%
ROA1.97%
Debt/Equity277.60
P/B Ratio4.6
Op. Cash FlowILA498.0M
Free Cash FlowILA-71875000
Industry P/E29.7

Technical Analysis

TrendBullish
RSI47.1
SupportILA 3,963.00
ResistanceILA 4,627.00
MA 20ILA 4,266.75
MA 50ILA 3,950.42
MA 200ILA 3,204.82
MACDBearish
VolumeStable
Fear & Greed Index91.79

Valuation

Fair ValueILA 667.95
GradeOvervalued
TypeGrowth
Dividend Yield0.59%

Risk Assessment

Beta0.09
Volatility28.61%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.